Podcasts about prudent use

In this transformative episode of The Over 50 Health & Wellness Show, host Kevin English sits down with Dr. Paul Kolodzik, a trailblazer in the field of metabolic health, to discuss the critical importance of managing our metabolic health as we age. Dr. Kolodzik shares his insights on the failings of traditional diets and medical interventions, and introduces an innovative approach to weight loss and health improvement through the use of continuous glucose monitoring (CGM). Show Notes:·      Introduction to Dr. Paul Kolodzik: Learn about Dr. Kolodzik's background in emergency medicine and his journey towards specializing in metabolic health, emphasizing the need for a shift from reactive to preventive healthcare.·      The Role of Continuous Glucose Monitoring (CGM): Discover how CGM technology, traditionally used by diabetics, is revolutionizing the way we approach weight loss and metabolic health, offering real-time insights into how our bodies process food.·      Combating Metabolic Diseases: Dr. Kolodzik discusses his comprehensive program for reversing metabolic diseases such as hypertension, high cholesterol, and prediabetes, highlighting the success stories from his practice.·      The Power of Lifestyle Changes: Explore the significance of low-carb diets and intermittent fasting in managing insulin resistance and improving overall health, as well as the critical role of strength training in maintaining muscle mass and preventing age-related decline.·      Prudent Use of Weight Loss Medications: Dr. Kolodzik shares his perspective on the cautious use of the latest weight loss medications, emphasizing their potential downsides and advocating for their use as a supplement to foundational lifestyle changes.·      Key Takeaways: Learn how to empower yourself to manage your future health through education and informed lifestyle choices, avoiding the pitfalls of the traditional medical system.·      Dr. Kolodzik's Book: Find out more about Dr. Kolodzik's book, "The Continuous Glucose Monitoring Revolution," where he outlines his program for metabolic health success.This episode is a must-listen for anyone over 50 looking to take control of their health and live their strongest, most vital life. Join us as we delve into the world of metabolic health and discover the tools and knowledge needed to make lasting changes.Whether you're looking to prevent metabolic diseases or seeking to improve your overall health and vitality, this episode provides invaluable insights and practical advice to guide you on your journey.Connect with Dr. Kolodzik: Website:https://www.metabolicmds.comTikTok: @dr.kolo.mdTwitter: @drkolomdInstagram: @metabolicmdsFacebook: metabolicmdLinkedIn: paulkolodzikYouTube:https://www.youtube.com/@MetabolicMD Book – The Continuous Glucose Monitor Revolution: Lose Weight, Look Great, and Live Longer with Continuous Glucose Monitoring by Dr. Paul Kolodzikhttps://www.amazon.com/dp/B0C4MP8MJNWant to rewrite the narrative of your life and health? Visit the link below to see if our 1:1 coaching services are a perfect fit for your long term goals: https://calendly.com/thesilveredge/coaching-inquiry Want more over 50 health and wellness goodness? Check out our private Facebook group: https://www.facebook.com/groups/silveredgefitness

"Human dignity is more than the right to be left alone."  What are the limitations of Libertarianism for Christians?   Does a decent society require a religious foundation?  Surely there are atheists who are kind, but as a society, there needs to be a moral culture that gives definition for freedom.  Freedom is not the same as autonomy.  Freedom is the ability to do the good.  But who is to say what is good without a revelation that comes from a higher authority than man himself?  Perhaps government and law cannot make us good, but isn't every sin destructive to society?  So shouldn't every sin be legislated?  Hodges and Vowell speculate on how to address the law.

Maryn McKenna is an independent journalist who specializes in public health, global health and food policy. She is a contributor to National Geographic, a Senior Fellow at the Schuster Institute for Investigative Journalism at Brandeis University, and the author of the critically acclaimed books Superbug (Simon & Schuster, 2010) and Beating Back the Devil (S&S 2004). She appears in the 2014 documentary “Resistance,” and her 2015 TED Talk, "What do we do when antibiotics don't work any more?" has been viewed 1.4 million times and translated into 32 languages. She writes for The New York Times, Newsweek, WIRED, Scientific American, Slate, The Atlantic, Nature, and The Guardian, among other publications, and received the 2014 Leadership Award from the Alliance for the Prudent Use of Antibiotics and the 2013 Byron H. Waksman Award for Excellence in the Public Communication of Life Sciences. Her new book, on antibiotics and agriculture, will be published by Penguin Random House in September 2017.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focused on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention. Part 3 will be published next week.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focussed on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focussed on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

Will we become defenseless against bacteria? Will bacteria always find a way to infect and even kill us? The emergence of antibiotic resistant strains of bacteria poses an enormous problem around the world. Scientists believe that the overuse of antibiotics is increasing the appearance of these pathogens. In the US, increasing casualties resulting from drug resistant staphylococcus infections received wide media attention. While antibiotics only work on bacterial infections, many patients and doctors regard antibiotics as a front-line form of treating any type of infection. Antibiotics are often prescribed because the specific pathogen that is causing an illness is often difficult to determine. In some cases they are used as a preventative measure. But is this the best defense? Are there ways to beat bacteria at their own game? On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 1 of this 3 part video series, Dr. Levy discusses the basics of microbial pathogens, bacteria, and antibiotic resistance. And, Dr. Tollefson outlines the various types and classes of antibiotic drugs, approved uses, and current levels of effectiveness. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

Will we become defenseless against bacteria? Will bacteria always find a way to infect and even kill us? The emergence of antibiotic resistant strains of bacteria poses an enormous problem around the world. Scientists believe that the overuse of antibiotics is increasing the appearance of these pathogens. In the US, increasing casualties resulting from drug resistant staphylococcus infections received wide media attention. While antibiotics only work on bacterial infections, many patients and doctors regard antibiotics as a front-line form of treating any type of infection. Antibiotics are often prescribed because the specific pathogen that is causing an illness is often difficult to determine. In some cases they are used as a preventative measure. But is this the best defense? Are there ways to beat bacteria at their own game? On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 1 of this 3 part video series, Dr. Levy discusses the basics of microbial pathogens, bacteria, and antibiotic resistance. And, Dr. Tollefson outlines the various types and classes of antibiotic drugs, approved uses, and current levels of effectiveness. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.